Combination light-based therapies to treat pancreatic cancer: a proof of concept

World Congress of the International Photodynamic Association Pub Date : 2019-08-07 DOI:10.1117/12.2525305

A. Ney, I. Mahamed, Andres Garcia-Sampedro, P. Selbo, P. Sancho, A. MacRobert, S. Pereira, P. Acedo

{"title":"Combination light-based therapies to treat pancreatic cancer: a proof of concept","authors":"A. Ney, I. Mahamed, Andres Garcia-Sampedro, P. Selbo, P. Sancho, A. MacRobert, S. Pereira, P. Acedo","doi":"10.1117/12.2525305","DOIUrl":null,"url":null,"abstract":"Pancreatic ductal adenocarcinoma remains one of the worst types of cancers mainly due to its late diagnosis, lack of effective therapies for advance disease and high chemoresistance. Novel therapeutic options that could improve patient quality of life and overall survival are therefore imperative. In this study, we describe the use of an original strategy based on photochemical internalisation (PCI) technology for pancreatic cancer treatment. Subcellular localisation of the photosensitiser meso-tetraphenylporphine-disulfonate (TPPS2a) was performed in PANC-1 cells, showing its preferential accumulation in lysosomes. Treatments with increasing concentrations of the ribosome-inactivating protein saporin or TPPS2a alone were compared with PCI-saporin. Metabolic activity and cell viability of PANC-1 cells were determined 96h post-illumination by MTT and trypan blue assays, respectively. Our results show that PCI using the photosensitiser TPPS2a, synergistically enhances the cytotoxic effects of saporin in PANC- 1 cells and could offer more effective treatment options for pancreatic cancer.","PeriodicalId":267589,"journal":{"name":"World Congress of the International Photodynamic Association","volume":"43 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Congress of the International Photodynamic Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1117/12.2525305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Pancreatic ductal adenocarcinoma remains one of the worst types of cancers mainly due to its late diagnosis, lack of effective therapies for advance disease and high chemoresistance. Novel therapeutic options that could improve patient quality of life and overall survival are therefore imperative. In this study, we describe the use of an original strategy based on photochemical internalisation (PCI) technology for pancreatic cancer treatment. Subcellular localisation of the photosensitiser meso-tetraphenylporphine-disulfonate (TPPS2a) was performed in PANC-1 cells, showing its preferential accumulation in lysosomes. Treatments with increasing concentrations of the ribosome-inactivating protein saporin or TPPS2a alone were compared with PCI-saporin. Metabolic activity and cell viability of PANC-1 cells were determined 96h post-illumination by MTT and trypan blue assays, respectively. Our results show that PCI using the photosensitiser TPPS2a, synergistically enhances the cytotoxic effects of saporin in PANC- 1 cells and could offer more effective treatment options for pancreatic cancer.

查看原文本刊更多论文

结合光疗法治疗胰腺癌:概念验证

胰腺导管腺癌仍然是最严重的癌症类型之一，主要原因是其诊断较晚，缺乏有效的晚期治疗方法和高化疗耐药性。因此，能够改善患者生活质量和总体生存率的新颖治疗方案势在必行。在这项研究中，我们描述了基于光化学内化(PCI)技术的胰腺癌治疗的原始策略的使用。在PANC-1细胞中进行了光敏剂中四苯基卟啉二磺酸盐(TPPS2a)的亚细胞定位，显示其在溶酶体中的优先积累。增加核糖体失活蛋白皂苷浓度或单独使用TPPS2a处理与pci皂苷处理进行比较。MTT法和台盼蓝法分别测定照射96h后PANC-1细胞的代谢活性和细胞活力。我们的研究结果表明，使用光敏剂TPPS2a的PCI可以协同增强皂苷对PANC- 1细胞的细胞毒作用，并可以为胰腺癌提供更有效的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Congress of the International Photodynamic Association

自引率

0.00%

发文量